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INTRODUCTION
The long-duration opioid buprenorphine has been used for several decades for treating acute and chronic pain, and is now also marketed for opioid addiction and withdrawal therapy.
Buprenorphine is a partial agonist at the mu opioid receptor and an antagonist at the kappa opioid receptor. Like other mu agonists, it causes analgesia, respiratory depression, miosis and mood changes, but unlike typical mu agonists there is a ceiling effect at higher doses (Cowan et JPET #193433 8 basolateral compartment of each well and 100 µl HBSSCM (without lucifer yellow) was added to the apical chamber. After incubating the cells for one hour at 37°C/95% humidity/5%CO 2 the receiver (apical) chamber and the donor chamber (basolateral) was sampled and the lucifer yellow-related fluorescence determined using a BioTEK SynergyMX plate reader (Winooski, VT). Wells were rejected if the permeability of the lucifer yellow was above 2%.
Apparent permeability (P app ) for both the MDCK wild type and the MDR1 transfected MDCK cells were calculated using eq.1, where (V r ) is the volume of buffer in the receiver, (A) is the surface area of the Transwell membrane (0.14 cm 2 ), (t) is the incubation time in seconds and drug (r) and (d) are the drug concentrations of the donor and receiver wells respectively at time t.
The directional ratio for each cell line was calculated by dividing the apparent permeability value for the basolateral-to-apical direction by the apparent permeability value for the apical-to-basolateral direction as eq. 2. 
The net efflux ratio was calculated by the dividing the directional ratio value for the MDR1 transfected cell line by the directional ratio of the untransfected MDCK cells using eq.3.
A net efflux ratio above 2.0 was the criterion used to define significant substrate-transporter interaction (Polli et al., 2001) .
prepared by the addition of d 5 -norfentanyl (100 ng/ml) as an internal standard. LC-MSMS was used to quantify norbuprenorphine and norbuprenorphine-3-glucuronide in brain and plasma, and all four compounds in the in vitro assay samples. LC-MSMS as analysis was performed as previously described (Brown et al., 2011 
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DISCUSSION
The purpose of this investigation was to evaluate P-gp-mediated transport of buprenorphine, norbuprenorphine, norbuprenorphine-3-glucuronide and buprenorphine-3-glucuronide in vitro, and test the hypothesis that P-gp mediated efflux limits brain access of norbuprenorphine (and possibly norbuprenorphine-3-glucuronide) and influences norbuprenorphine antinociception. P-gp transfected MDCK cells were used to screen for P-gp substrates specifically, rather than as a model for blood-brain transport more generally. The major result was that norbuprenorphine was a P-gp substrate both in vitro and in vivo. As measured by the net efflux ratio in transfected cells, P-gp-mediated norbuprenorphine efflux was substantial, and approximated that of the unambiguous P-gp substrate loperamide (Polli et al., 2001 ) (9 vs 13, respectively). P-gp-mediated norbuprenorphine brain efflux was also observed in vivo. In mdr1a(+/+) animals, the norbuprenorphine brain/plasma ratio was negligible and constant. In contrast, in mdr1a(-/-) animals, the norbuprenorphine brain/plasma ratio increased steadily, approaching unity. This demonstrates that P-gp represents a major barrier to norbuprenorphine entering the brain and that elimination of transporter function resulted in increased norbuprenorphine brain concentrations, which essentially equaled plasma concentrations. Thus, absent P-gp-mediated efflux, norbuprenorphine accumulates in the brain until the drug is equally distributed between brain and plasma. The low norbuprenorphine brain concentration in mdr1a(+/+) mice is likely due to a combination of low passive permeability and substantial P-gp-mediated efflux (Ohtani et al., 1995) .
P-gp-mediated brain access significantly influenced the pharmacologic effect of norbuprenorphine. Antinociception was greater in both magnitude and duration in mdr1a (-/-) compared to mdr1a(+/+) mice despite the mdr1a(-/-) mice receiving one-fourth the norbuprenorphine dose of the mdr1a(+/+) mice. Moreover, the duration of norbuprenorphine antinociception in mdr1a(-/-) mice was even greater than that observed after a maximally , 1960; Aceto et al., 1969) . This has been shown to be mediated through the central μ 2 -opioid receptor subtype (Nath et al., 1994) . The mdr1a(-/-) mice also exhibited loss of righting reflex, another μ 2 -opioid receptor mediated effect (Oka et al., 1992; Kamei et al., 1996) . Together, all these findings strongly support the hypothesis that P-gp regulates brain access of norbuprenorphine, and that greater norbuprenorphine brain access in P-gp-deficient mice caused greater antinociceptive and behavioral effects.
Norbuprenorphine is a mu, delta, and kappa receptor agonist, as shown in vitro (Huang et al., 2001; Brown et al., 2011) . Thus, the poor antinociceptive effects of norbuprenorphine in wild-type mice could be due to limited brain exposure rather than low intrinsic analgesic efficacy of norbuprenorphine. While norbuprenorphine was shown to have an analgesic effect onefourth that of buprenorphine following an intraventricular dose in rats (Ohtani et al., 1995) , intraventricular dosing in a wild type animal may still be accompanied by substantial P-gp mediated efflux and therefore less overall brain exposure. norbuprenorphine-3-glucuronide transport was evaluated, along with that of buprenorphine and buprenorphine-3-glucuronide. In vitro, neither buprenorphine, buprenorphine-3-glucuronide, nor norbuprenorphine-3-glucuronide were P-gp substrates. The net efflux ratio was approximately 1 for each. In vivo, norbuprenorphine-3-glucuronide brain/plasma concentration ratios after norbuprenorphine were very small, and unaffected by P-gp deficiency, indicating that norbuprenorphine-3-glucuronide has limited brain access, and P-gp does not influence norbuprenorphine-3-glucuronide efflux or brain concentrations in vivo.
JPET #193433 20 for other opioids, such as alfentanil (Kalvass et al., 2007) . Thus the degree to which P-gp impedes brain access and antinociception is greater for norbuprenorphine than these other opioids.
The role of P-gp in mediating brain access of norbuprenorphine in humans, and the pharmacologic contribution of norbuprenorphine to buprenorphine clinical effects, are unknown.
If, however, these are clinically relevant, then findings described in this report may explain, in , 2007) . Nevertheless, the interaction caused some subjects became sedated. The adverse side effects after buprenorphine/atazanavir were attributed to inhibition of CYP3A4-mediated buprenorphine metabolism by atazanvir. However atazanavir is also a P-gp inhibitor (Bierman et al., 2010) , and, in light of the findings in the present report, it is possible that atazanavir-enhanced buprenorphine effects could be attributable, at least in part, to P-gp inhibition and increased norbuprenorphine brain access. Tipranavir/ritonavir had no effect on plasma buprenorphine concentrations but diminished norbuprenorphine concentrations to one-fifth of control, and had no effect on opioid withdrawal (Bruce et al., 2009) . While this was considered mechanistically unclear, tipranavir and ritonavir are both P-gp inhibitors (Storch et al., 2007) , and might have therefore increased brain norbuprenorphine exposure and Two limitations of the present investigation merit mention. Buprenorphine was found to bind readily to the polystyrene used for the in vitro transwell studies, which potentially confounded the accurate determination of the extent of transcellular movement. Due to differences in the surface areas of the apical and basolateral compartments, correction for nonspecific binding was not possible. Therefore the buprenorphine data should be interpreted carefully. Nonspecific buprenorphine binding has also been reported previously (Tournier et al., 2010) . Due to the unexpectedly large effect of P-gp on brain norbuprenorphine access, there
was not sufficient overlap of norbuprenorphine brain concentrations between mdr1a(-/-) and mdr1a(+/+) mice to separately model the brain concentration-antinociception data in the two groups, thus they were modeled together.
In conclusion, the limited antinociceptive effect of norbuprenorphine is due to P-gp mediated inhibition of brain access. P-gp does not influence brain disposition of buprenorphine-3-glucuronide or norbuprenorphine-3-glucuronide. These findings add to the complexity of buprenorphine pharmacology. There was no effect of norbuprenorphine on tidal volume.
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